

Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas

Fabrice Jardin,^{1,2} Philippe Ruminy,¹ Jean-Pierre Kerckaert,³ Françoise Parmentier,¹ Jean-Michel Picquenot,¹ Sabine Quief,³ Céline Villenet,³ Gérard Buchonnet,¹ Mario Tosi,⁴ Thierry Frebourg,⁴ Christian Bastard,¹ and Hervé Tilly^{1,2}


¹INSERM U618, European Institute of Peptide Research (IFR23), Rouen; ²Centre Henri Becquerel, Department of Hematology, Rouen; ³INSERM U837, Université de Lille 2, IFR 114 and from the Institut de Recherches sur le Cancer, Lille; ⁴INSERM U614, Institut Hospitalo-Universitaire de Recherche, Rouen, France

Citation: Jardin F, Ruminy P, Kerckaert J-P, Parmentier F, Picquenot J-M, Quief S, Villenet C, Buchonnet G, Tosi M, Frebourg T, Bastard C, and Hervé Tilly. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas. Haematologica 2008;93(04):XXXX. doi: 10.3324/haematol.12251

QMPSF assa	Primer sequences (Forward / Reverse)	Amplicon size	Gene Chromosomal location			
	CAAACCTCCTCACACAGCCCACT / GAGACTGTCCAACTTGACCCTC	147	8q24	MYC 8q24		
	CTACAGCCACCTGAAGTCCAA/TGCAAGCAAGGGTTCAAAGAC	203	17p13	TP53		
assay 1	COCAACGCACCGAATAGTTAC / GTCTGTGATTACAAACCCCTTCTG	210	9p21	CDKN2A		
	ATTTTCAGAATCACAAACCCCTAGA/ATGCGTGTCCTCAGAGTTAGCC	220	12p13	CDKN1B		
	AAATGGACTTTTCTCCCCTACTCG / TCGAGTGGTCAAGCGCAAAG	247	6q16	SIM1		
	AGCAAAAGGCATCTTTTCAGAAG / CTGGTCAGAAGGTCTCCGCAA	150	2p12	c-REL		
	GGCCGGTGTCTTTCCTCTTT / TCAGTGGCAGGTTGTTCTCCA	178	3q27	BCL6		
assay 2	GCCTCTGTTTGATTTCTCCTGG /AGCTTTGTTTCATGGTACATCACTG	213	18q21	BCL2		
	GTGGACTGGGAATCCTTGGG / CATCTTGAGGCTGACATTTGTATAAG	200	6q22	PTPRK		
	GCAGCCAAGAAGATGTGAAAGAG/ ACATACTGGGCAGGGGCTTATTC	236	12g13	MDM2		
reference ger	GCGCATCTGTTGATGAAAGAAA / TGGGTGGGAATATCAGGGTC	165	22q11	CECR1		

Supplementary Table S1. Sequences and locations of primers used in the QMPSF assays¹

¹two decanucleotides extensions, for the forward and for the reverse primers respectively, were added on the 5' side of these oligonucleotides. Their sequences are available upon signing a material and confidential information transfer agreement.



Supplementary Table S2. Gene copy number abnormalities detected by QMPSF in 77 de novo DLBCL.

^adetermined by immunohistochemistry

UPN patient	TP53 alle	lic status			TP53 mutations			p53 IHC	
	QMPSF	CGH	Exon	Codon	p53 structural domain	Nucleotide	Amino acid		
954	deletion	deletion	.5	147	S3	GTT > GGT	Val > Gly	+	
1073	deletion	ND	5	175	1,2	CGC > CAC	Arg > His	+	
934	deletion	ND	5	141	83	TGC > CGC	Cys > Arg	+	
968	deletion	ND	8	278	810	CTT > TCT	Leu > Ser	+	
150	deletion	deletion	5.	175	1.2	CGC > CAC	Arg > His	1	
385	385	germline	45	5	133	S2*	ATG > AAG	Met > Lys	+
			gerinline	6	218	85	GTG > GAG	Val > Glu	*
112	572	and the same	Carl Carl	5	161	S4	GCC > ACC	Ala > Thr	
	germlinė	ND	7	248	L3	CGG > TGG	Arg > Trp	-	
1216	germline	germline	5	163	84	TAC > TAT	Tyr > Tyr	- 3	
479	germline	ND	5	179	311	CAT > TAT	His > Tyr	*	
1010	germline	ND	7	249	1.3	AGG > AAG	Arg > Lys		
671	germline	ND	8	273	S10	CGT > CAT	Arg > His	-	
1190	germline	ND	7	246	1.3	ATG > ACG	Met > Thr	+	

Supplementary Table S3. TP53 mutations, TP53 allelic status assessed by QMPSF/CGH and p53 protein expression in 12 DLBCL.

Supplementary Figure 1

